An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
2023-08-01
عنوان الدراسة
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
داعم الدراسة
Novartis
دواء الدراسة
ribociclib / letrozole
رقم بروتوكول الدراسة
CLEE011A2404
حالة الدراسة
Completed
موقع الدراسة
NGHA-R , KFSH&RC-R , KFSH , KAMC , NGHA-J , KFMC
مرحلة الدراسة
3b
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.